Predicting pathological complete response in breast cancer using the extracellular vesicle-based liquid biopsy

Active Project Grant Awarded Last action

Award ID
HT94252410271
Recipient
Awarding agency
Obligated
$562,500

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date 86% complete
Place of performance
Pittsburgh, PA 15213, USA

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

The Defense Health Agency awarded a $562,500 project grant to Captis Diagnostics Inc., a self-certified small disadvantaged business, to develop an extracellular vesicle-based liquid biopsy assay for predicting pathological complete response in breast cancer patients. The grant project runs from April 1, 2024 to March 31, 2027 and is funded through the Military Medical Research and Development program (CFDA 12.420). This program supports a range of biomedical research to improve health outcomes for military service members, veterans, and their families. Captis Diagnostics has a portfolio of federal contract and grant awards, demonstrating its expertise in advancing innovative diagnostic technologies for cancer and neurological disorders through minimally invasive liquid biopsies and extracellular vesicle isolation methods.

Quick answers

Who received award HT94252410271?

HT94252410271 was awarded to Captis Diagnostics Inc. by Defense Health Agency (Department of Defense) on April 1, 2024.

How much is award HT94252410271 worth?

$562,500 has been obligated on HT94252410271.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login